Display options
Cite
Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Oncol Stem Cell Res. 2015;9(1):10-4
Ramzi, M., Rezvani, A., & Dehghani, M. (2015). GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. International journal of hematology-oncology and stem cell research, 9(1), 10-4.
Ramzi, Mani, et al. "GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study." International journal of hematology-oncology and stem cell research vol. 9,1 (2015): 10-4.
Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Oncol Stem Cell Res. 2015 Jan 01;9(1):10-4. PMID: 25802695; PMCID: PMC4369228.
Copy Download .nbib Format: NLM
Share it on

Int J Hematol Oncol Stem Cell Res. 2015 Jan 01;9(1):10-4.

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study.

International journal of hematology-oncology and stem cell research

Mani Ramzi, Aliraza Rezvani, Mehdi Dehghani

Affiliations

  1. Department of Medical Oncology and Hematology & Bone marrow Transplantaion, Namazi Hospital, Shiraz University of Medical Science Shiraz, Iran.

PMID: 25802695 PMCID: PMC4369228

Abstract

BACKGROUND: Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different combinations.

PATIENTS AND METHODS: A Total of 44 patients identified with refractory or relapsed Hodgkin's Lymphoma were considered eligible for this study. The Patients were randomly divided into two groups of 22, one of which were treated with GDP regimen (gemcitabine, dexamethasone and cisplatin) and the other with EHSAP regimen (etoposide, methyl prednisolone, cisplatin and cytarabine) in a prospective manner. The results of each group were compared.

RESULTS: There were 27.3% complete response, 31.8% more than 50% response, and 40.9% no response with GDP. ESHAP results were 29.5%, 24% and 45.5%, respectively.

CONCLUSION: There is no significant difference in response rate between GDP and ESHAP regimens as salvage chemotherapy in refractory or relapsed Hodgkin's Lymphoma.

Keywords: Hodgkin Lymphoma; Relapsed Hodgkin Lymphoma; Salvage Chemotherapy

References

  1. Blood. 2003 Aug 1;102(3):834-8 - PubMed
  2. N Engl J Med. 2000 Jan 13;342(2):83-9 - PubMed
  3. Indian J Med Res. 2008 Apr;127(4):366-9 - PubMed
  4. Pediatr Dent. 2002 Jul-Aug;24(4):321-5 - PubMed
  5. Br J Haematol. 2005 Oct;131(1):129-34 - PubMed
  6. Anemia. 2011;2011:698586 - PubMed
  7. N Engl J Med. 2005 Aug 4;353(5):498-507 - PubMed
  8. J Clin Epidemiol. 1997 Feb;50(2):121-6 - PubMed
  9. Br J Haematol. 1981 Aug;48(4):533-43 - PubMed
  10. Arch Pediatr. 2000 Jan;7(1):16-24 - PubMed
  11. Acta Haematol. 1999;101(4):178-84 - PubMed
  12. Interact Cardiovasc Thorac Surg. 2010 Jan;10 (1):67-8 - PubMed
  13. Br J Haematol. 1999 Apr;105 Suppl 1:19-26 - PubMed
  14. Am J Trop Med Hyg. 2005 Jan;72(1):47-59 - PubMed
  15. Arch Dis Child. 1996 Jun;74(6):502-6 - PubMed
  16. Hematol Cell Ther. 1999 Nov;41(5):217-21 - PubMed
  17. J Trop Pediatr. 1987 Dec;33(6):326-8 - PubMed
  18. Niger J Med. 2004 Jan-Mar;13(1):40-3 - PubMed

Publication Types